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thioridazine, our evidence suggests that it is incorrect to invoke a
"site specific" action for this drug on dopamine receptors in
mesolimbic areas of human brain. Its anticholinergic properties
probably represent an adequate explanation for the rarity of drug-
induced parkinsonism associated with thioridazine treatment.








ENTEROBACTER RESISTANT TO AMOXYCILLIN/
CLAVULANATE
SIR,-We wish to report the isolation of a strain of Enterobacter
cloacae which is sensitive in vitro to ampicillin but resistant to
amoxycillin/clavulanate (’Augmentin’). The organism was isolated
from a wound swab taken from an infected leg ulcer ofa woman aged
70. Disc testing on ’Isosensitest’ agar by a modification of Stokes’
method’ revealed a measurable zone of inhibition by a 10 g
ampicillin disc but negligible inhibition by a 30 g augmentin disc
(figure). The results were similar on subculture. When a
Disc sensitivity testing of Enterobacter cloacae.
Control Escherichia coliNCTC 10418 on outer part of plate. Augmentin disc
(AUG) contains 20 J.l.g amoxycillin, 10 g clavulanic acid.
chromogenic cephalosporin2 (nitrocefin) was used to test for
(3-lactamase production, the colonies in the immediate presence of
the augmentin disc showed strong activity, in contrast to weak
activity elsewhere in the culture. Further work is in progress to seek
an explanation for this effect. Clavulanic acid can induce
(3-lactamase activity in Enterobacter Spp.3 3
The patient was treated with oxytetracycline and metronidazole
(there was no history of recent use of either ampicillin or
augmentin). The infected ulcer improved and six days later the
Enterobacter cloacae could no longer be isolated. The strain was
sensitive in vitro to tetracycline. This case shows that an augmentin-
resistant organism can be sensitive to ampicillin. Isolates should
therefore be tested against both antibacterial agents.
We believe this to be the first reported isolation of an ampicillin-
sensitive, augment in-resistant organism. Enterobacter cloacae,
however, is not a common pathogen and this is likely to be a rare
phenomenon.
Public Health Laboratory,
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HYPOCARNITINAEMIA IN DISORDERS OF
ORGANIC ACID METABOLISM
. SIR,-The report by Dr Roe and Dr Bohan of a response to
L-carnitine in a child with propionyl CoA carboxylase (PCC)
deficiency (June 19, p. 1411) is an important observation in the
management of this serious disorder. We have observed a dramatic
clinical response to carnitine in an infant with a severe
encephalomyopathy due to homocystinuria (5,10-methylenetetra-
hydrofolate reductase deficiency).’ This enzymatic defect causes a
secondary form of systemic carnitine deficiency, presumably
because of defective methylation of lysine. The infant was
hypomethioninaemic, with reduced muscle and plasma carnitine
levels (table, patient 1).
We have since measured plasma free-carnitine2 in several infants
and children with various metabolic diseases, and some examples
are given in the table.
PLASMA FREE-CARNITINE IN VARIOUS METABOLIC DISORDERS
*Normal plasma free-carnitine 54-3 3 nmol/ml (range 31 -1-81 ’6)’
It is of interest that the plasma carnitine was low in the first
patient identified with PCC deficiency in whom the enzyme defect
was established in 1969.4 This young adult is in excellent health
despite reduced plasma carnitine. The addition of biotin to her low-
protein regimen seemed to improve her wellbeing even further.
Plasma carnitine was especially low during an acute illness with
metabolic acidosis treated by dialysis (a procedure associated with
reduced plasma carnitine5). We found an infant with Leigh’s disease
whose affected (pathologically confirmed) sibling died with low
plasma carnitine; and also one of two children with multiple
carboxylase deficiency (the one with bouts of acute metabolic
acidosis).
Roe and Bohan report a reduced urinary carnitine but does this
reflect the plasma level? It is important to establish this relationship
since urinary levels in infants are lower than those in older childrenand adults. A reduced protein intake does not seem to reduce
plasma carnitine in patients (maple syrup urine disease, classical
homocystinuria, or phenylketonuria) who have been on altered
aminoacid diets or reduced protein intake.
Nonetheless the observation by Rose and Bohan is important.
The effectiveness of treatment in some metabolic diseases is
presently limited even with a maximum vitamin-coenzyme response
or dietary aminoacid/protein restriction. The response to biotin, for
example, may be very slight in PCC deficiency, especially during
acute episodes of metabolic acidosis. In the long-term care of
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patients with organic acidaemias, it would be important to establish
whether the continuous use of carnitine improves protein tolerance,
which would also make life more tolerable. Roe and Bohan suggest
that their baby with PCC deficiency tolerated greater amounts of
protein while taking carnitine.
Carnitine supplementation may be a new approach to the
treatment of several diseases causing reduced muscle tone,
hyperammonaemia, reduced protein tolerance, and lactic acidosis.
Carnitine is known to reverse the defect in mitochondrial
(3-oxidation and oxidative phosphorylation accompanying a
number of organic acidaemis.8 Fortunately, oral carnitine seems to
be safe and nontoxic.
Pediatric Neurology Laboratory,
and Departments of Pediatrics and Neurology,
University of Michigan Medical School,
Ann Arbor, Michigan 48109, U.S A
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RANDOMISED TRIAL OF FETAL MOVEMENT
COUNTING
SIR,-Scientific evaluation of the various tests of fetal wellbeing is
easier when the test in question aims to identify a baby with a
relatively unambiguous abnormality (for example, a neural tube
malformation), than when its purpose is the identification of
conditions which prompt non-specific "diagnoses" such as fetal
compromise, placental insufficiency, and chronic fetal asphyxia.
In these latter circumstances, the assessment is more difficult not
only because a firm diagnosis is frequently elusive after as well as
before delivery, but also because treatment which aims to improve
the outcome is often interposed between the results of the test and
the outcomes against which the test results are being compared. In
these circumstances, a poor correlation between test results and
outcome may indeed be the consequence of a poorly predictive test,
but it may also be the result of successful treatment. These
considerations, which we have discussed in more detail elsewhere, 1
are relevant in assessing your suggestion (Aug. 7, p. 309) that
formalised fetal movement counting may lead to a false-positive
("alarm") rate as high as 500/0-that is, that half of those cases in
which delivery was prompted by test results have normal Apgar
scores.
In evaluating formalised fetal movement counting, and indeed
any other tests of fetal "wellbeing", there is often no alternative to
conducting a randomised trial in which the test in question, together
with the treatment prompted by the test results, is compared with an
alternative test and resultant treatment.2 So far, only a handful of
such studies have been reported,3-7 among them the trial of
formalised fetal movement counting conducted by Neldam.
We agree with you that it is important to replicate Neldam’s
evaluation and we have designed a trial with this objective. The
success of the trial we envisage would depend on the support of
consultant obstetricians. We have so far received an encouraging
response to an informal approach to all obstetricians in one health
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region, and we would be pleased to hear from anyone else who
would be interested in participating.





HORMONES AND FLUID RETENTION IN CIRRHOSIS
SIR,-In your editorial (June 12, p. 1341) you discuss the role of
aldosterone in sodium retention and the possibility that
"aldosterone receptors are hypersensitive in cirrhotic patients". If
this is true, an abrupt reduction in plasma aldosterone should
initiate natriuresis. We have used the angiotensin I converting
enzyme inhibitor, captopril, in a patient with profound oedema and
ascites due to alcoholic cirrhosis. The accompanying figure shows
hormone and electrolyte data before and during captopril treatment
Change in plasma angiotensin, aldosterone, and electrolytes during
captopril treatment in a patient with cirrhotic oedema.
Captopril dose was 30 mg on day 3, 125 mg on day 4, 400 mg on day 5, and
450 mg daily thereafter.
while the patient was studied on a fixed sodium intake (32
mmol/day) during conditions of controlled posture and metabolic
balance. Before captopril, plasma and urine aldosterone were high
and supine plasma angiotensin II was also raised. After starting
captopril, both plasma angiotensin II and plasma aldosterone fell
dramatically and low levels of both hormones were observed for at
least the following six days of study. Despite this fall, body weight
did not change and no increase in sodium excretion ensued. Supine
systolic blood pressure fell from 110 to 85 mm Hg (lowest level 75
mm Hg) but plasma urea (5 - 5 mmol/1) and creatinine (0’ 12 mmol/1)
did not change from pretreatment values.
The failure to achieve a natriuresis in the face of such reductions
